BFRG

Bullfrog AI Holdings, Inc.

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.

Bullfrog AI Holdings, Inc. (BFRG) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.8) B+ (3.8) B (3.2) C (2.5) C+ (2.6) B- (3.0)
2026-11-10 C+ (2.8) B+ (3.7) B (3.2) C+ (2.7) C+ (2.6) B- (3.0)
2026-11-03 C+ (2.8) B+ (3.7) B (3.2) C (2.2) C+ (2.7) B- (2.9)
2026-10-27 C+ (2.8) B+ (3.6) B (3.2) C- (2.0) C+ (2.6) B- (2.9)
2026-10-20 C+ (2.8) B+ (3.6) B (3.2) D+ (1.5) C+ (2.6) C+ (2.8)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe